Stage
No active trials
Next date
None yet
Trials
0 active
1 in total · 1 in the EU
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “VE202 is a rationally defined, live biotherapeutic product for oral administration.”In the company’s words, NCT05370885 on ClinicalTrials.gov
- Tested for
- Ulcerative Colitis, Colitis, Ulcerative
- Main trialPhase 2
- “A Phase 2 study to evaluate the safety, efficacy, and microbiota changes of VE202 in patients with mild to moderate ulcerative colitis (UC).”In the company’s words, NCT05370885 on ClinicalTrials.gov
Other drugs for Ulcerative Colitis
- TofacitinibPfizer · Phase 3
- UpadacitinibAbbVie · Phase 3
- RisankizumabAbbVie · Phase 3
- UstekinumabJohnson & Johnson (Janssen) · Phase 3
- IcotrokinraJohnson & Johnson (Janssen) · Phase 3
- ObefazimodAbivax S.A. · Phase 3
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Terminated | 29 Aug 2025 | VE202 in Patients With Mild-to-Moderate Ulcerative Colitis |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026